OptimizeRx (NASDAQ:OPRX) announced its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.15), Fidelity Earnings reports. The firm had revenue of $5.00 million during the quarter, compared to analyst estimates of $7.21 million. OptimizeRx had a negative net margin of 5.32% and a negative return on equity of 4.19%.
NASDAQ OPRX traded down $0.35 on Friday, reaching $10.13. The company had a trading volume of 161,551 shares, compared to its average volume of 91,799. The firm has a market capitalization of $170.46 million, a price-to-earnings ratio of 202.60, a price-to-earnings-growth ratio of 1.50 and a beta of 0.42. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.80 and a current ratio of 6.80. OptimizeRx has a 1-year low of $8.92 and a 1-year high of $17.24. The company’s fifty day moving average is $13.59 and its 200-day moving average is $14.43.
In related news, CEO William J. Febbo bought 5,000 shares of OptimizeRx stock in a transaction that occurred on Wednesday, November 6th. The stock was purchased at an average cost of $10.38 per share, with a total value of $51,900.00. 8.40% of the stock is currently owned by corporate insiders.
OptimizeRx Company Profile
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Recommended Story: What is Net Asset Value (NAV)?
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.